FindTrial
Sign In

MVA85A

BIOLOGICAL13 trials

Sponsors

University of Oxford, Mark Hatherill

Conditions

HIVImmunogenicitySafetyTuberculosisTuberculosis (TB)

Phase 1

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
CompletedNCT00427830
University of OxfordTuberculosis
Start: 2003-05-31End: 2005-01-31Target: 16Updated: 2007-01-29
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously
CompletedNCT00427453
University of OxfordTuberculosis
Start: 2003-06-30End: 2005-03-31Target: 12Updated: 2007-01-29
T-Cell Turnover Following Vaccination With MVA85A
CompletedNCT00548444
University of OxfordTuberculosis
Start: 2007-10-31End: 2010-01-31Updated: 2010-01-18
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A
CompletedNCT00653770
University of OxfordTuberculosis
Start: 2007-09-30End: 2010-01-31Updated: 2010-02-09
A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV
CompletedNCT00731471
University of OxfordTuberculosis
Start: 2008-08-31End: 2011-01-31Target: 24Updated: 2011-03-28
Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A
CompletedNCT01683773
University of OxfordTuberculosis
Start: 2012-09-30End: 2014-08-31Updated: 2014-09-17
Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults
CompletedNCT01829490
University of OxfordTuberculosis
Start: 2013-07-31End: 2016-04-30Updated: 2016-05-12
Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults
CompletedNCT01879163
University of OxfordTuberculosis (TB)
Start: 2013-07-31End: 2014-12-31Updated: 2014-12-16
Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity
CompletedNCT01954563
University of OxfordTuberculosis
Start: 2013-10-31End: 2016-01-31Updated: 2016-01-28
EMaBS TB Vaccine Study
CompletedNCT03681860
University of OxfordImmunogenicity, Safety
Start: 2019-07-01End: 2021-05-24Updated: 2022-08-05

Phase 2

A Study of MVA85A in Healthy Children and Infants
CompletedNCT00679159
University of OxfordTuberculosis
Start: 2008-02-29End: 2009-12-31Updated: 2010-02-09
Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination
CompletedNCT01650389
Mark HatherillHIV, Tuberculosis
Start: 2012-10-31End: 2015-05-31Updated: 2015-09-30
Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents
CompletedNCT02178748
University of OxfordTuberculosis
Start: 2014-06-30End: 2015-01-31Updated: 2015-01-30

Related Papers

Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and Possible Future Outcomes.
2020-09-0545 citations
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
PLoS Medicine2019-04-3066 citations
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.
2018-09-194 citations
Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial
Clinical Infectious Diseases2017-09-2235 citations
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
PLoS neglected tropical diseases2017-05-0431 citations
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
Vaccine2016-02-0642 citations
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
PLoS ONE2015-11-0340 citations
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A
BMC Infectious Diseases2014-12-0127 citations
Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
PLoS ONE2013-10-152 citations
Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
PLoS ONE2013-06-2813 citations
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
2012-11-1020 citations
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
2011-06-0170 citations
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
2009-06-1652 citations